Moderna Inc (MRNA)
108.85
+0.96
(+0.89%)
USD |
NASDAQ |
Apr 24, 16:00
107.82
-1.03
(-0.95%)
Pre-Market: 08:50
Moderna Enterprise Value: 33.07B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 33.07B |
| April 23, 2024 | 32.70B |
| April 22, 2024 | 31.39B |
| April 19, 2024 | 30.22B |
| April 18, 2024 | 30.45B |
| April 17, 2024 | 31.00B |
| April 16, 2024 | 31.14B |
| April 15, 2024 | 31.16B |
| April 12, 2024 | 31.65B |
| April 11, 2024 | 32.37B |
| April 10, 2024 | 32.42B |
| April 09, 2024 | 34.13B |
| April 08, 2024 | 31.63B |
| April 05, 2024 | 30.79B |
| April 04, 2024 | 30.55B |
| April 03, 2024 | 30.15B |
| April 02, 2024 | 31.07B |
| April 01, 2024 | 31.83B |
| March 28, 2024 | 32.20B |
| March 27, 2024 | 33.74B |
| March 26, 2024 | 32.52B |
| March 25, 2024 | 33.66B |
| March 22, 2024 | 31.76B |
| March 21, 2024 | 31.25B |
| March 20, 2024 | 30.86B |
| Date | Value |
|---|---|
| March 19, 2024 | 31.64B |
| March 18, 2024 | 31.32B |
| March 15, 2024 | 31.16B |
| March 14, 2024 | 31.01B |
| March 13, 2024 | 32.18B |
| March 12, 2024 | 33.68B |
| March 11, 2024 | 34.27B |
| March 08, 2024 | 30.84B |
| March 07, 2024 | 29.48B |
| March 06, 2024 | 28.88B |
| March 05, 2024 | 27.91B |
| March 04, 2024 | 28.08B |
| March 01, 2024 | 27.72B |
| February 29, 2024 | 26.64B |
| February 28, 2024 | 28.64B |
| February 27, 2024 | 28.15B |
| February 26, 2024 | 27.32B |
| February 23, 2024 | 28.25B |
| February 22, 2024 | 29.39B |
| February 21, 2024 | 24.86B |
| February 20, 2024 | 24.63B |
| February 16, 2024 | 25.16B |
| February 15, 2024 | 26.21B |
| February 14, 2024 | 24.23B |
| February 13, 2024 | 24.01B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.978B
Minimum
Aug 05 2019
187.56B
Maximum
Aug 09 2021
43.56B
Average
38.95B
Median
May 17 2023
Enterprise Value Benchmarks
| Merck & Co Inc | 349.66B |
| Pfizer Inc | 206.77B |
| Eli Lilly and Co | 718.54B |
| Johnson & Johnson | 364.33B |
| Novavax Inc | 180.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 217.00M |
| Revenue (Quarterly) | 2.813B |
| Total Expenses (Quarterly) | 2.807B |
| EPS Diluted (Quarterly) | 0.55 |
| Gross Profit Margin (Quarterly) | 66.97% |
| Profit Margin (Quarterly) | 7.71% |
| Earnings Yield | -11.40% |
| Normalized Earnings Yield | -11.27 |